These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37858132)

  • 1. Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study.
    Ottaiano A; De Luca A; Santorsola M; Scognamiglio G; Di Mauro A; Chiodini P; Lambiase M; Sacco A; Petrillo A; Granata V; Fusco R; Mercadante E; Martucci N; De Luca G; Rocca A; Celentano E; Crispo A; Di Gennaro P; Tatangelo F; Ferrara G; Izzo F; Belli A; Patrone R; Delrio P; Rega D; De Franciscis S; Muto P; Ravo V; Di Franco R; Borzillo V; Santagata S; Rea G; Castaldo D; Pace U; De Feo G; Scala S; Nasti G; Normanno N
    BMC Cancer; 2023 Oct; 23(1):1010. PubMed ID: 37858132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives.
    Ottaiano A; Santorsola M; Circelli L; Trotta AM; Izzo F; Perri F; Cascella M; Sabbatino F; Granata V; Correra M; Tarotto L; Stilo S; Fiore F; Martucci N; Rocca A; Picone C; Muto P; Borzillo V; Belli A; Patrone R; Mercadante E; Tatangelo F; Ferrara G; Di Mauro A; Scognamiglio G; Berretta M; Capuozzo M; Lombardi A; Galon J; Gualillo O; Pace U; Delrio P; Savarese G; Scala S; Nasti G; Caraglia M
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
    Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study.
    Nicosia L; Franceschini D; Perrone-Congedi F; Molinari A; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Cappelli A; D'Angelo E; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Vavassori V; Maranzano E; Maria Magrini S; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Loi M; Jereczek-Fossa BA; Casamassima F; Osti MF; Scorsetti M; Alongi F
    Clin Transl Radiat Oncol; 2023 Mar; 39():100568. PubMed ID: 36935855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort.
    Hompland I; Bruland ØS; Hølmebakk T; Poulsen JP; Stoldt S; Hall KS; Boye K
    Acta Oncol; 2017 Oct; 56(10):1317-1323. PubMed ID: 28557540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
    Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
    Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
    Moretto R; Rossini D; Zucchelli G; Lonardi S; Bergamo F; Santini D; Cupini S; Tomasello G; Caponnetto S; Zaniboni A; Antoniotti C; Pietrantonio F; Buonadonna A; Marmorino F; Bordonaro R; Fea E; Tamburini E; Boccaccino A; Grande R; Aprile G; Falcone A; Cremolini C
    Eur J Cancer; 2020 Nov; 139():81-89. PubMed ID: 32979645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
    Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
    Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.
    Kroese TE; Takahashi Y; Lordick F; van Rossum PSN; Ruurda JP; Lagarde SM; van Hillegersberg R; Verhoeven RHA; van Laarhoven HWM
    Eur J Cancer; 2023 Jan; 179():65-75. PubMed ID: 36509000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
    Baker S; Mou B; Jiang W; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Berrang T; Bang A; Chng N; Matthews Q; Tyldesley S; Olson RA
    Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):849-855. PubMed ID: 36302495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.
    Leonhardt CS; Stamm T; Hank T; Prager G; Strobel O
    ESMO Open; 2023 Dec; 8(6):102067. PubMed ID: 37988953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
    Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
    Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
    Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
    Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic Disease.
    Kim J; Chang JS; Sung W; Kim JS; Kim TH; Choi SH; Kim KH; Ko H; Lee HS; Jeon S; Shin SJ; Liu M; Olson R
    Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):883-891. PubMed ID: 36007725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiation therapy for metastatic lung metastases.
    Kimura T; Fujiwara T; Kameoka T; Adachi Y; Kariya S
    Jpn J Radiol; 2022 Oct; 40(10):995-1005. PubMed ID: 36097233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.
    Kroese TE; van Laarhoven HWM; Nilsson M; Lordick F; Guckenberger M; Ruurda JP; D'Ugo D; Haustermans K; van Cutsem E; van Hillegersberg R; van Rossum PSN
    Eur J Cancer; 2022 May; 166():254-269. PubMed ID: 35339868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pattern of failure after Stereotactic Radiation Therapy (SRT) for oligo-metastases: predictive factors for poly-progression.
    Franceschini D; Cozzi L; Vernier V; Marzo AM; Marini B; Stefanini S; Navarria P; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5173-5179. PubMed ID: 36357737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.
    Belluomini L; Dodi A; Caldart A; Kadrija D; Sposito M; Casali M; Sartori G; Ferrara MG; Avancini A; Bria E; Menis J; Milella M; Pilotto S
    Transl Lung Cancer Res; 2021 Jul; 10(7):3369-3384. PubMed ID: 34430373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.